IPSEN, OOO
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
- Conditions
- Pregnancy Related
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 20
- Registration Number
- NCT06258902
- Locations
- 🇺🇸
Virtual Research Coordination Center Odevixibat (BYLVAY) Pregnancy Surveillance Program, Wilmington, North Carolina, United States
A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly
- Conditions
- Gastro-enteropancreatic Neuroendocrine TumorAcromegaly
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 20
- Registration Number
- NCT06253897
- Locations
- 🇺🇸
Pearl IRB, Indianapolis, Indiana, United States
CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb Spasticity
- Conditions
- Upper Limb Injury
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 113
- Registration Number
- NCT06245772
- Locations
- 🇫🇷
CH Bagnères, Bagnères-de-Bigorre, France
🇫🇷CH Bar le Duc, Bar-le-Duc, France
🇫🇷Besançon - CHU/CRRF de Bréguille/Salin les bains, Besançon, France
A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
- Conditions
- Fibrodysplasia Ossificans Progressiva
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 70
- Registration Number
- NCT06089616
- Locations
- 🇨🇦
Edmonton Clinic Health Academy (ECHA)- University of Alberta, Edmonton, Canada
🇨🇦Bone Research and Education Centre, Oakville, Canada
🇨🇦University Health Network (UHN) - Toronto General, Toronto, Canada
A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
- Conditions
- Spasticity as Sequela of Stroke
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 1051
- Registration Number
- NCT06055725
- Locations
- 🇮🇹
AOU San giovanni di Dio e Ruggi d'aragona Univ. di Salerno, Salerno, Italy
🇮🇹Neurological Rehabilitation Unit- Policlinico Borgo Roma., Verona, Italy
🇮🇹Neuromotor And Cognitive Rehabilitation Research Centre; Dep. Of Neurological, Neuropsychological, Morphological And Movement Sciences; Univ. Of Verona - Neurological Rehabilitation Unit- Policlinico Borgo Roma, Verona, Italy
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
- Conditions
- Episodic Migraine
- Interventions
- Other: Placebo
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 714
- Registration Number
- NCT06047457
- Locations
- 🇺🇸
SDS Clinical Trials, Orange, California, United States
🇩🇪Emovis GmbH, Berlin, Germany
🇺🇸Central Research Associates, Birmingham, Alabama, United States
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
- Conditions
- Chronic Migraine
- Interventions
- Other: Placebo
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 720
- Registration Number
- NCT06047444
- Locations
- 🇮🇹
IRCCS San Raffaele Pisana, Roma, Italy
🇮🇹PU Campus Bio-Medico di Roma, Roma, Italy
🇵🇱Synexus Polska Sp. z o.o., Gdynia, Poland
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
- Conditions
- Primary Biliary Cholangitis (PBC)
- Interventions
- Other: Matched 80 mg placebo
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 276
- Registration Number
- NCT06016842
- Locations
- 🇧🇪
Gent University Hospital, Gent, Belgium
🇧🇪Algemeen Ziekenhuis Delta, Roeselare, Belgium
🇧🇷Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre, Brazil
A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NET
- Conditions
- Neuroendocrine Tumors
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 191
- Registration Number
- NCT05922579
- Locations
- 🇦🇺
CAPPRE, Sidney, Australia
A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in Italy
- Conditions
- Prostate Cancer
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 167
- Registration Number
- NCT05759273
- Locations
- 🇮🇹
Humanitas Gavazzeni, Bergamo, Italy
🇮🇹AOU Policlinico "Gaspare Rodolico", Catania, Italy
🇮🇹Azienda Ospedaliera Universitaria Careggi, Firenze, Italy